Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in

Sarepta Navigates Regulatory Hurdles and Pivotal Catalysts

Sarepta Therapeutics is navigating significant challenges, including patient deaths linked to its gene therapy Elevidys, but is poised for several key catalysts. The company plans to file for full FDA approval of its Duchenne muscular dystrophy (DMD) exon skippers, Amondys 45 and Vyondys 53, by the end of April, despite a failed confirmatory study, banking on real-world and safety data. This review is anticipated to take 12 months. Additionally, a Phase 1b study testing the immunosuppressive regimen sirolimus with Elevidys in nonambulatory DMD patients, aimed at mitigating liver injury risk, is expected to read out in the fourth quarter. Sarepta's partner Roche also announced a pivotal trial for Elevidys in Europe, signaling confidence despite a prior negative EMA recommendation.

• Sarepta is pursuing full FDA approval for its Duchenne muscular dystrophy (DMD) exon skippers, Amondys 45 and Vyondys 53, by the end of April. This regulatory filing is proceeding despite the drugs failing a confirmatory study in November 2025, with the company relying on real-world and safety data to support their favorable profile. These therapies currently account for approximately 50% of Sarepta's total sales under an accelerated approval pathway.
• To address safety concerns following patient deaths linked to liver failure, Sarepta is conducting a Phase 1b study of an immunosuppressive regimen, sirolimus, with Elevidys in 25 nonambulatory DMD patients. This regimen is designed to mitigate the risk of acute liver injury associated with the gene therapy. A positive readout from this study, expected in the fourth quarter, could enable Elevidys's return to this patient population, potentially doubling its revenue.
• Sarepta's partner, Roche, has committed to launching a pivotal trial for Elevidys in Europe, a significant move following a negative recommendation from the European Medicines Agency (EMA) in July 2025. This substantial investment by Roche is viewed as a strong positive signal, indicating their belief in the trial's success and the therapy's eventual acceptance by physicians and patients in the European market.

Navigating Full FDA Approval for Sarepta's Exon Skippers

Recent clinical studies in Duchenne muscular dystrophy have provided important insights into emerging therapeutic approaches, though outcomes have been mixed. These trials span gene therapy, exon-skipping strategies, and novel corticosteroid alternatives, representing the current landscape of DMD therapeutic development.

• CIFFREO Phase 3 Trial evaluated fordadistrogene movaparvovec, a recombinant AAV9-based gene therapy encoding mini-dystrophin, in 122 ambulatory boys aged 4-8 years but failed to meet its primary endpoint of improved NSAA scores at 52 weeks (difference 0.09, 95% CI -1.46 to 1.64, p=0.91), with 99% of treated participants experiencing adverse events including vomiting (76%), pyrexia (62%), and serious adverse events in 32% versus 14% in placebo group

• Vamorolone trials VBP15-002 and VBP15-004 demonstrated efficacy across five motor outcomes (STANDV, NSAA, 6MWD, RWV, and CLIMBV) in 169 steroid-naïve participants aged 4-7 years, with this novel dissociative glucocorticoid showing comparable motor benefits to prednisone while potentially offering improved safety profile, leading to FDA approval as AGAMREE

• TAMDMD Phase 3 trial tested tamoxifen 20mg daily as adjunct to corticosteroids in 66 patients through a 48-week open-label extension but showed no significant difference in motor function between early and delayed treatment groups, with good overall tolerability but no clinical evidence of efficacy in delaying disease progression

• Eteplirsen and exon-skipping therapies continue to face efficacy challenges despite FDA accelerated approval, with current PMO drugs targeting exons 51, 53, and 45 providing mutation-class-specific benefits, while next-generation approaches including peptide-conjugated PMOs and antibody-oligonucleotide conjugates aim to improve tissue exposure

• Delandistrogene moxeparvovec (ELEVIDYS) became the first FDA-approved gene therapy for DMD using AAV-mediated micro-dystrophin delivery, though long-term efficacy and durability remain unconfirmed and immune-mediated toxicities including myositis, myocarditis, and liver injury require careful patient monitoring and immunoprophylaxis strategies

New Clinical Strategies to Expand Elevidys's Impact

Recent clinical trials in Duchenne muscular dystrophy have employed diverse study designs ranging from large multicenter randomized controlled trials to small pilot studies and natural history analyses. These trials consistently utilize validated functional outcome measures, with the North Star Ambulatory Assessment and 6-minute walk test serving as primary endpoints across multiple studies, while increasingly incorporating advanced imaging biomarkers and body composition analyses.

Addressing Critical Unmet Needs in Duchenne Muscular Dystrophy

Recent literature reveals that Duchenne muscular dystrophy continues to present significant therapeutic challenges despite advancing research efforts. While current treatments offer symptom management and may prolong survival, no curative therapies exist, creating urgent demand for disease-modifying approaches. The field is increasingly focused on precision medicine strategies targeting specific patient populations based on their underlying genetic mutations.

• Absence of curative treatments - No definitive cure exists for DMD, with current standard of care limited to symptom management and palliative approaches that fail to address the underlying genetic defects

• Limited therapeutic options for genetic diversity - More than 8,558 different mutations in the DMD gene require personalized therapy approaches, yet most DMD variants are rare, making it practically impossible to generate appropriate models for each unique mutation

• Research infrastructure gaps - Only a few immortalized muscle cell lines with DMD mutations are available for research, while obtaining muscle cells from patients requires invasive biopsies with limited proliferative capacity

• Poor compliance with care guidelines - Less than 27% of patients across Germany, Italy, UK, and US met all absolute care recommendations, with compliance ranging from as low as 9% in Italy to 37% in the UK

• Gene therapy delivery limitations - Current rAAV vectors face major obstacles including immunotoxicity and hepatotoxicity risks from high-dose administration, while microdystrophin exhibits inherent functional limitations

• Healthcare disparities - Significant treatment gaps exist globally, with Brazil's public health system showing 25-month diagnostic delays compared to 10 months in private care, resulting in earlier loss of ambulation and reduced life expectancy

• Cardiac targeting challenges - Substantial difficulties persist in achieving effective cardiac-specific delivery strategies, as DMD cardiomyopathy remains a leading cause of mortality

• Clinical trial design gaps - Older non-ambulant patients have historically been excluded from trials, limiting therapeutic development for this population with significant unmet needs

Sarepta's Strategic Gambit: Expanding DMD Reach Amidst Regulatory Hurdles

Sarepta Therapeutics is navigating a complex landscape in Duchenne muscular dystrophy (DMD) with a series of high-stakes strategic moves. The company's decision to seek full FDA approval for its exon-skipping therapies, Amondys 45 and Vyondys 53, despite a confirmatory trial miss, represents a bold bet on the totality of evidence, including real-world and safety data. This approach, if successful, could redefine regulatory expectations for rare disease therapies, particularly those granted accelerated approval. However, the 12-month review period introduces considerable uncertainty, and the FDA's ultimate decision will be a critical determinant of the long-term commercial viability and perceived efficacy of these established products.

Simultaneously, Sarepta is proactively addressing a key safety concern for its gene therapy, Elevidys, by investigating sirolimus as an immunosuppressive regimen to mitigate liver injury. This is a crucial development, as existing evidence indicates sirolimus (rapamycin), an mTOR inhibitor, possesses immunosuppressive properties and has shown promise in ameliorating dystrophic phenotypes in preclinical models. If the Phase 1b study in nonambulatory patients demonstrates a favorable safety and efficacy profile, it could significantly broaden the eligible patient population for Elevidys, extending its reach beyond the current ambulatory 4-5 year old indication. However, the introduction of an additional immunosuppressant carries inherent risks, including potential new side effects or drug-drug interactions that will require careful monitoring.

Further bolstering confidence in Elevidys, Sarepta's partner Roche is initiating a pivotal trial in Europe, a significant step given the prior negative recommendation from the EMA. This move underscores a strong belief in the therapy's potential and a commitment to global market penetration. While this signals a long-term vision, it also highlights the ongoing challenge of aligning regulatory perspectives across different regions. The outcomes of these initiatives will collectively shape Sarepta's future, influencing investor confidence, market share, and ultimately, access to transformative therapies for patients with DMD.